Avalo Therapeutics (AVTX) Cost of Revenue (2017 - 2024)
Avalo Therapeutics posted quarterly Cost of Revenue of $714000.0 for Q3 2024, up 189.07% year-on-year from $247000.0 in Q4 2023, and up 108.16% on a QoQ basis from $343000.0 in Q2 2024.
Avalo Therapeutics (AVTX) has 8 years of Cost of Revenue data on file, last reported at $714000.0 in Q3 2024.
- For the quarter ending Q3 2024, Cost of Revenue rose 189.07% year-over-year to $714000.0; the trailing twelve-month figure through Jun 2025 stood at $1.1 million (up 153.23% YoY), and the FY2023 full-year result was $1.3 million, down 62.61% from the prior year.
- Cost of Revenue for Q3 2024 stood at $714000.0, up from $343000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $2.1 million in Q4 2020 and bottomed at -$221000.0 in Q4 2023.
- The 5-year median for Cost of Revenue is $551000.0 (2023), against an average of $572421.1.
- The widest annual swing landed in 2022, when Cost of Revenue soared 1787.95%; it then sank 135.65% in 2023.
- A 5-year view of Cost of Revenue shows it stood at $2.1 million in 2020, then slumped by 80.0% to $424000.0 in 2021, then jumped by 46.23% to $620000.0 in 2022, then tumbled by 135.65% to -$221000.0 in 2023, then soared by 423.08% to $714000.0 in 2024.
- The last three Cost of Revenue figures came in at $714000.0 (Q3 2024), $343000.0 (Q2 2024), and $80000.0 (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 714,000.00 |
| Sep 30, 2024 | 714,000.00 |
| Jun 30, 2024 | 343,000.00 |
| Jun 30, 2024 | 343,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | -221,000.00 |
| Dec 31, 2023 | -221,000.00 |
| Sep 30, 2023 | 247,000.00 |
| Sep 30, 2023 | 247,000.00 |
| Jun 30, 2023 | 708,000.00 |
| Jun 30, 2023 | 708,000.00 |
| Mar 31, 2023 | 551,000.00 |
| Mar 31, 2023 | 551,000.00 |
| Dec 31, 2022 | 620,000.00 |
| Dec 31, 2022 | 620,000.00 |
| Sep 30, 2022 | 528,000.00 |
| Sep 30, 2022 | 528,000.00 |
| Jun 30, 2022 | 1.57 Mn |
| Jun 30, 2022 | 1.57 Mn |
| Mar 31, 2022 | 720,000.00 |
| Mar 31, 2022 | 720,000.00 |
| Dec 31, 2021 | 424,000.00 |
| Dec 31, 2021 | 424,000.00 |
| Sep 30, 2021 | 908,000.00 |
| Sep 30, 2021 | 908,000.00 |
| Jun 30, 2021 | 83,000.00 |
| Jun 30, 2021 | 83,000.00 |
| Mar 31, 2021 | 77,000.00 |
| Mar 31, 2021 | 77,000.00 |
| Dec 31, 2020 | 2.12 Mn |
| Dec 31, 2020 | 2.12 Mn |
| Sep 30, 2020 | 77,000.00 |
| Sep 30, 2020 | 77,000.00 |
| Jun 30, 2020 | 653,000.00 |
| Jun 30, 2020 | 653,000.00 |
| Mar 31, 2020 | 677,000.00 |
| Mar 31, 2020 | 677,000.00 |
| Dec 31, 2019 | 547,701.00 |
| Dec 31, 2019 | 547,701.00 |
| Sep 30, 2019 | 132,382.00 |
| Sep 30, 2019 | 132,382.00 |
| Jun 30, 2019 | 1.50 Mn |
| Jun 30, 2019 | 1.50 Mn |
| Mar 31, 2019 | 396,276.00 |
| Mar 31, 2019 | 396,276.00 |
| Dec 31, 2018 | -4.85 Mn |
| Dec 31, 2018 | -4.85 Mn |
| Sep 30, 2018 | 3.11 Mn |
| Sep 30, 2018 | 3.11 Mn |
| Jun 30, 2018 | 2.04 Mn |
| Jun 30, 2018 | 2.04 Mn |
| Mar 31, 2018 | 16,196.00 |
| Mar 31, 2018 | 16,196.00 |
| Dec 31, 2017 | 636,000.00 |
| Dec 31, 2017 | 636,000.00 |